Recent Finacing
Recent Raise
NBE‑Therapeutics develops antibody–drug conjugates for oncology using Transpo‑mAb antibody discovery, SMAC site‑specific enzymatic conjugation and an anthracycline toxin platform, advancing ROR1-targeting NBE‑002 into clinical development.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
